Skip to main content

Catalyst Calendar

Fri, Aug 7, 2026

1 updates

8:45 AM

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Enrollment • Phase 2Enrollment completion Tue, Jun 30, 2026atossatherapeutics.com

Tue, Jul 28, 2026

1 updates

8:30 AM

Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer

atossatherapeutics.com

Tue, Jul 21, 2026

1 updates

8:30 AM

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

atossatherapeutics.com

Fri, Jun 12, 2026

1 updates

5:30 PM

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

atossatherapeutics.com

Thu, Jun 11, 2026

1 updates

8:00 AM

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

atossatherapeutics.com

Wed, May 27, 2026

1 updates

8:30 AM

Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial

Presentation / Abstract • Phase 2Poster presentation Mon, Jun 1, 2026, 1:30 PM CTatossatherapeutics.com

Wed, May 20, 2026

1 updates

4:45 PM

Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

atossatherapeutics.com